Bortezomib therapy in myelofibrosis: a phase II clinical trial.
Mesa
R A
RA
Verstovsek
S
S
Rivera
C
C
Pardanani
A
A
Hussein
K
K
Lasho
T
T
Wu
W
W
Tefferi
A
A
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D006801:Humans; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib